Ubie, Inc., a healthcare AI company with the mission of “Developing a Healthcare Guide for Everyone,” earned $26.2 million in its first round of Series C investment. Among the new investors in the round are the wholly owned subsidiaries of NEC Capital Solutions Limited, The Dai-ichi Life Insurance Company, Limited, Egg FORWARD, Inc., Norinchukin Capital Co., Ltd., and NVenture Capital Limited. One of the current participants in the round is SUZUKEN CO., LTD. To now, Ubie has raised $59.8 million.
Ubie is one of the only businesses with a medical data platform that communicates directly with both patients and healthcare providers. Ubie offers two services that stress the “medical questionnaire” as a gateway to healthcare, using AI as its key technology.
In order to discover linked conditions and provide more detailed, helpful health information, patients are provided access to an “AI-powered symptom checker” that asks around 20 questions about their symptoms. Since its launch, it has won the trust of 5 million people per month, including those in Japan and the US.
Ubie offers “AI-powered patient intake,” a service that expedites the medical interview process, at medical facilities. This service is based on a database with more than 50,000 medical papers from across the world that was put together by more than 50 practicing doctors. The service has been utilized by more than 1,000 medical facilities worldwide, which has improved their operational efficiency.
By establishing connections between patients, healthcare providers, and pharmaceutical firms via the medical data platform it is developing, Ubie will seek to address the following medical challenges in Japan and the U.S.
- Make sure that patients go to the right hospital at the right time.
- Making sure that doctors have access to current, pertinent knowledge from the vast amount of research on illnesses and rare diseases outside of their field of expertise.
- Make sure that pharmaceutical companies continue to give patients the right information and scientific findings about their conditions.
Series C funding will be used to assist business development in both Japan and the US in order to build a medical data platform that connects patients, healthcare providers, and pharmaceutical companies.
The current healthcare system is suffering from various losses as a result of the fragmentation of information owned by patients, medical institutions, and pharmaceutical businesses, not just in Japan but also in other countries, according to Yoshinori Abe, MD, the co-founder and CEO of Ubie. This funding effort aims to accelerate collaboration with pharmaceutical companies and provide an unrivaled patient-centered medical experience through the usage of Ubie’s data platform. Ubie already has commercial relationships with more than 20 prominent pharmaceutical companies in Japan and other countries, which furthers Ubie’s mission to develop a blueprint for universal healthcare.
